Learning about blood cancers from human induced pluripotent stem cells

We study malignant and pre-malignant disorders of hematopoiesis (myelodysplastic syndrome, MDS; myeloproliferative neoplasms, MPN; acute myeloid leukemia, AML; inherited bone marrow failure syndromes, IBMFS; and clonal hematopoiesis, CH) with human induced pluripotent stem cell (iPSC) models and primary patient cells.

We use somatic cell reprogramming and CRISPR-mediated genome editing technologies to develop genetically faithful human pluripotent stem cell models of blood diseases, with which we gain insights into disease mechanisms and discover new therapeutic targets.

We are an international team located in the Leon and Norma Hess Center for Science and Medicine at Icahn School of Medicine at Mount Sinai.

We are part of the Center for Advancement of Blood Cancer Therapies (CABCT) and work closely with the Stem Cell Engineering Core (SCEC) and the Bioinformatics for Next Generation Sequencing (BiNGS) shared resource facility.